← All trials
NCT03026842
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2017
- Primary completion
- Dec 1, 2023
- Completion date
- Oct 1, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 180
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Jilin UniversityLead sponsor
- Jilin UniversityReponsible party - principal investigator
- Jilin UniversityStudy director
- Jilin UniversityCollaborator
- Dalian Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.